New Triple-Threat attack on advanced stomach cancer tested before surgery
NCT ID NCT07277439
Summary
This study is testing if adding an immune-boosting drug (thymosin alpha 1) to a standard pre-surgery treatment works better for people with stage III cancer where the stomach meets the esophagus. The standard treatment combines immunotherapy, chemotherapy, and radiation to shrink the tumor before an operation. Researchers will compare two groups to see which approach leads to more patients having no visible cancer cells left after surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Nanjing Medical Unviersity
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.